Merck’s Arcoxia “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is seeking additional safety and efficacy data for the COX-2 inhibitor, the company says. Merck is working with international regulatory agencies on labeling changes for Arcoxia to address safety issues prompted by the Vioxx withdrawal.
You may also be interested in...
Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
Company expects to hear from FDA in April on 30 mg and 60 mg once-daily doses of the Vioxx follow-on drug.
Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
Company expects to hear from FDA in April on 30 mg and 60 mg once-daily doses of the Vioxx follow-on drug.
Merck’s Vioxx Successor Arcoxia May Be Closer To Market
FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.